We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cellectar Biosciences Inc | NASDAQ:CLRB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0222 | -8.05% | 0.2535 | 0.26 | 0.2696 | 0.2752 | 0.252 | 0.27 | 800,426 | 22:00:00 |
“2023 was a year of significant progress for Cellectar, culminating in the January announcement of the positive data from our pivotal study of iopofosine I 131 in Waldenstrom’s macroglobulinemia,” said James Caruso, president, and CEO of Cellectar. “We continue to focus on the preparation of our NDA, which we plan to submit in the second half of 2024 and in parallel request accelerated approval, which if granted, would provide a six-month review period for the NDA. Our data in WM is truly impressive and we look forward to providing this meaningful new therapeutic for patients in a disease with limited treatment options.”
Fourth Quarter and Recent Corporate Highlights
2023 Financial Highlights
Conference call & Webcast DetailsCellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions. Stockholders and other interested parties may participate in the conference call by dialing 1-888-886-7786 (in the U.S.) or 1-416-764-8658 (outside the U.S.). The call will be available via webcast by clicking HERE or on the Events page of the company’s website.
About Cellectar Biosciences, Inc.Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Forward-Looking Statement DisclaimerThis news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations regarding the CLOVER WaM pivotal trial. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2023. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
Contacts
MEDIA:Claire LaCagninaBliss Bio Health315-765-1462clacagnina@blissbiohealth.com
INVESTORS:Chad KoleanChief Financial Officerinvestors@cellectar.com
CELLECTAR BIOSCIENCES, INC.CONSOLIDATED BALANCE SHEETS | ||||||||
December 31, | December 31, | |||||||
2023 | 2022 | |||||||
ASSETS | ||||||||
CURRENT ASSETS: | ||||||||
Cash and cash equivalents | $ | 9,564,988 | $ | 19,866,358 | ||||
Prepaid expenses and other current assets | 888,225 | 663,243 | ||||||
Total current assets | 10,453,213 | 20,529,601 | ||||||
Fixed assets, net | 1,090,304 | 418,641 | ||||||
Right-of-use asset, net | 502,283 | 560,334 | ||||||
Long-term assets | 23,566 | 75,000 | ||||||
Other assets | 6,214 | 6,214 | ||||||
TOTAL ASSETS | $ | 12,075,580 | $ | 21,589,790 | ||||
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Accounts payable and accrued liabilities | $ | 9,178,645 | $ | 5,478,443 | ||||
Warrant liability | 3,700,000 | — | ||||||
Lease liability | 58,979 | 50,847 | ||||||
Total current liabilities | 12,937,624 | 5,529,290 | ||||||
Lease liability, net of current portion | 494,003 | 552,981 | ||||||
TOTAL LIABILITIES | 13,431,627 | 6,082,271 | ||||||
COMMITMENTS AND CONTINGENCIES (Note 10) | ||||||||
STOCKHOLDERS’ (DEFICIT) EQUITY: | ||||||||
Series D preferred stock, 111.11 shares authorized; 111.11 shares issued and outstanding as of December 31, 2023 and 2022 | 1,382,023 | 1,382,023 | ||||||
Series E-2 preferred stock, 1,225.00 shares authorized; 319.76 and 0.00 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 4,677,632 | — | ||||||
Common stock, $0.00001 par value; 170,000,000 shares authorized; 20,744,110 and 9,385,272 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 207 | 94 | ||||||
Additional paid-in capital | 210,066,630 | 193,624,445 | ||||||
Accumulated deficit | (217,482,539 | ) | (179,499,043 | ) | ||||
Total stockholders’ (deficit) equity | (1,356,047 | ) | 15,507,519 | |||||
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | $ | 12,075,580 | $ | 21,589,790 |
CELLECTAR BIOSCIENCES, INC.CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
Year Ended December 31, | |||||||
2023 | 2022 | ||||||
COSTS AND EXPENSES: | |||||||
Research and development | $ | 28,211,460 | $ | 19,219,603 | |||
General and administrative | 10,749,183 | 9,594,170 | |||||
Total costs and expenses | 38,960,643 | 28,813,773 | |||||
LOSS FROM OPERATIONS | (38,960,643 | ) | (28,813,773 | ) | |||
OTHER INCOME (EXPENSE): | |||||||
Warrant issuance expense | (470,000 | ) | — | ||||
Gain on valuation of warrants | 1,000,000 | — | |||||
Interest income, net | 387,147 | 152,519 | |||||
Total other income, net | 917,147 | 152,519 | |||||
LOSS BEFORE INCOME TAXES | (38,043,496 | ) | (28,661,254 | ) | |||
INCOME TAX BENEFIT | (60,000 | ) | (60,000 | ) | |||
NET LOSS | $ | (37,983,496 | ) | $ | (28,601,254 | ) | |
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE | $ | (3.11 | ) | $ | (4.05 | ) | |
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE | 12,221,571 | 7,055,665 |
1 Year Cellectar Biosciences Chart |
1 Month Cellectar Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions